By the same authors

From the same journal

Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey

Research output: Contribution to journalArticle

Published copy (DOI)


  • A. Davies
  • A. Bakhai
  • C. Schmitt
  • A. Barrett
  • P. Graham-Clarke
  • M. Sculpher


Publication details

JournalJournal of Medical Economics
DatePublished - 1 Jan 2013
Issue number4
Pages (from-to)510-521
Original languageEnglish


Objective: To evaluate the long-term cost-effectiveness of 12-months treatment with prasugrel vs clopidogrel from four European healthcare systems' perspectives (Germany, Sweden, the Netherlands, and Turkey). Methods: In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel. Prasugrel reduced the composite end-point (cardiovascular death, MI, or stroke), but increased TIMI major bleeding. A Markov model was constructed to facilitate a lifetime horizon for the analysis. A series of risk equations constructed using individual patient data from TRITON-TIMI 38 was used to estimate risks of clinical events. Quality-adjusted life-years (QALYs) were derived by weighting survival time by estimates of health-related quality-of-life. Incremental cost-effectiveness is presented based on differences in treatments' mean costs and QALYs for the licensed population in TRITON-TIMI 38, and the sub-groups of UA-NSTEMI, STEMI, diabetes, and the 'core clinical cohort' (

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations